Cargando…

Reinduction of Hedgehog Inhibitors after Checkpoint Inhibition in Advanced Basal Cell Carcinoma: A Series of 12 Patients

SIMPLE SUMMARY: For patients with advanced basal cell carcinoma (aBCC) limited treatment options are available. In this situation, hedgehog inhibitors (HHIs) are approved as first-line treatment. Upon treatment failure or intolerance, a second-line treatment with PD1 inhibitors (PD1i) is an option....

Descripción completa

Detalles Bibliográficos
Autores principales:	DeTemple, Viola K., Hassel, Jessica C., Sachse, Michael M., Grimmelmann, Imke, Leiter, Ulrike, Gebhardt, Christoffer, Eckardt, Julia, Pföhler, Claudia, Angela, Yenny, Hübbe, Hanna, Gutzmer, Ralf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9658899/ https://www.ncbi.nlm.nih.gov/pubmed/36358887 http://dx.doi.org/10.3390/cancers14215469

Ejemplares similares

Long-Term Management of Advanced Basal Cell Carcinoma: Current Challenges and Future Perspectives
por: Heppt, Markus V., et al.
Publicado: (2022)

Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS
por: KAATZ, Martin, et al.
Publicado: (2022)

Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade
por: Niewolik, Jacqueline, et al.
Publicado: (2022)

Monocyte chemoattractant protein 1 as a potential biomarker for immune checkpoint inhibitor‐associated neurotoxicity
por: Möhn, Nora, et al.
Publicado: (2023)

Case Report: Sustained Remission Due to PD-1-Inhibition in a Metastatic Melanoma Patient With Depleted B Cells
por: Wulfken, Lena Margarethe, et al.
Publicado: (2021)

Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer.
por: Hejna, M., et al.
Publicado: (1998)

The Role of Recombination Activating Gene (RAG) Reinduction in Thymocyte Development in Vivo
por: Yannoutsos, Nikos, et al.
Publicado: (2001)

Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany
por: Mohr, Peter, et al.
Publicado: (2022)

Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn’s Disease With a Loss of Response
por: Heron, Valerie, et al.
Publicado: (2022)

Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry
por: Haist, Maximilian, et al.
Publicado: (2022)

Reinduction of Hormone Sensitivity to Goserelin following Chemotherapy with Vinorelbine in Castration-Resistant Prostate Cancer
por: Grenader, Tal, et al.
Publicado: (2010)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Clofarabine with topotecan, vinorelbine, and thiotepa reinduction regimen for children and young adults with relapsed AML
por: Ramaswamy, Kavitha, et al.
Publicado: (2022)

Extra intravenous Ustekinumab reinduction is an effective optimization strategy for patients with refractory Crohn’s disease
por: Yao, Jiayin, et al.
Publicado: (2023)

Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity
por: Koch, Elias A. T., et al.
Publicado: (2022)

Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis
por: Koch, Elias A. T., et al.
Publicado: (2021)

A Single Center Experience With Long-Term Ustekinumab Use and Reinduction in Patients With Refractory Crohn Disease
por: Bennett, Audrey, et al.
Publicado: (2020)

Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor Therapy
por: Möhn, Nora, et al.
Publicado: (2020)

Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: A retrospective analysis of 75 patients
por: Schaefer, Tim, et al.
Publicado: (2017)

Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis
por: Zaremba, Anne, et al.
Publicado: (2021)

Reinduction of the Temporarily Deferred Donors for Laying the Foundation of Safe and Sustainable Blood Supplies: A Review in the Indian Context
por: Arcot, Priyadarsini Jayachandran, et al.
Publicado: (2022)

Genes Involved in Immune Reinduction May Constitute Biomarkers of Response for Metastatic Melanoma Patients Treated with Targeted Therapy
por: Berciano-Guerrero, Miguel-Angel, et al.
Publicado: (2022)

Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study
por: Stege, H. M., et al.
Publicado: (2021)

Anti‐PD‐1 antibodies in metastatic uveal melanoma: a treatment option?
por: Bender, Carolin, et al.
Publicado: (2017)

Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition
por: Hassel, Jessica C., et al.
Publicado: (2023)

Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG
por: Franklin, Cindy, et al.
Publicado: (2023)

Reinduction of Bevacizumab in Combination with Pegylated Liposomal Doxorubicin in a Patient with Recurrent Glioblastoma Multiforme Who Progressed on Bevacizumab/Irinotecan
por: Almubarak, Mohammed, et al.
Publicado: (2008)

Multiplex CRISPR/Cas9 genome editing in hematopoietic stem cells for fetal hemoglobin reinduction generates chromosomal translocations
por: Samuelson, Clare, et al.
Publicado: (2021)

Expression of Glioma-associated oncogene homolog 1 as biomarker with sonidegib in advanced basal cell carcinoma
por: Dummer, Reinhard, et al.
Publicado: (2020)

Immunoprevention of Basal Cell Carcinomas with Recombinant Hedgehog-interacting Protein
por: Vogt, Annika, et al.
Publicado: (2004)

Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in BRAFV600 Melanoma: Current Status and Future Perspectives
por: Welti, Michèle, et al.
Publicado: (2022)

Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients
por: Leiter, Ulrike, et al.
Publicado: (2020)

Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients
por: Lodde, Georg, et al.
Publicado: (2021)

Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study
por: Lee, Scott D., et al.
Publicado: (2016)

Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study
por: Fucà, Giovanni, et al.
Publicado: (2022)

Hedgehog signaling pathway and its targets for treatment in basal cell carcinoma
por: Cucchi, Danilo, et al.
Publicado: (2012)

Hedgehog signaling promotes basal progenitor expansion and the growth and folding of the neocortex
por: Wang, Lei, et al.
Publicado: (2016)

Basal Cell Carcinoma and Hedgehog Pathway Inhibitors: Focus on Immune Response
por: Gambini, Donatella, et al.
Publicado: (2022)

Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG
por: Haist, Maximilian, et al.
Publicado: (2023)

Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study
por: Kähler, Katharina C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7hi3j2mpceo7t3310ch5lnakgp